Healthcare Resource Utilization 12 Months Following Initiation of Olanzapine/Samidorphan: Real-World Assessment of Patients With Schizophrenia

INTRODUCTION

- Antipsychotic medications are effective options for managing the symptoms of schizophrenia and improving quality of life¹ • Despite their efficacy, atypical antipsychotics are associated with adverse effects, including weight gain, which can
- negatively affect persistence on treatment, as well as patients' health and well-being²⁻⁴
- The combination of olanzapine and samidorphan (OLZ/SAM) provides the established antipsychotic efficacy of olanzapine while mitigating olanzapine-associated weight gain⁵⁻⁷
- OLZ/SAM treatment was associated with significant reductions in acute healthcare resource utilization (HCRU) in a previous real-world study comparing the 6 months before and after initiating OLZ/SAM⁸
- This analysis builds on the previous 6-month analysis⁸ by extending the pre- and post-OLZ/SAM periods to 12 months

OBJECTIVE

• To assess and compare HCRU among adult patients with schizophrenia in the 12 months before and after initiating OLZ/SAM treatment

METHODS

Data Source


• This retrospective analysis used inpatient (IP), outpatient (OP), and pharmacy claims data from October 18, 2020, to December 31, 2023, from Komodo Healthcare Map, a fully deidentified US-based database of ~150 million patients covered by a commercial (66%), Medicaid (27%), or Medicare Advantage (7%) plan

Patients and Study Design

Inclusion Criteria

- Age ≥18 years with ≥1 pharmacy or medical claim for OLZ/SAM
- ≥12 months of continuous enrollment with medical and pharmacy benefits before (baseline period) and after (fixed followup period) the index date (date of first medical or pharmacy claim for OLZ/SAM)
- ≥1 medical claim for schizophrenia during the baseline or follow-up period
- Patients with medical claims for both schizophrenia and bipolar I disorder were assigned an indication of schizophrenia Exclusion Criterion
- A pharmacy or medical claim for OLZ/SAM during the baseline period

Figure 1. Study Design



OLZ/SAM, combination olanzapine and samidorpha

Outcomes

- Baseline patient demographics, clinical characteristics, and medication use
- Treatment patterns of OLZ/SAM, including adherence, persistence, and discontinuation
- HCRU, including IP admissions, emergency department (ED) and OP visits, average number of IP days in hospital per patient, and average length of stay (LOS) per hospitalization in each of the following categories:
- All-cause HCRU
- Mental health-related HCRU
- Schizophrenia-related HCRU

Statistics

- Baseline patient demographics and clinical characteristics are reported as numbers and percentages for categorical variables and means and SDs for continuous variables
- The following unadjusted pairwise comparisons were used for 12-month pre-post comparisons:
- Paired t-test for normally distributed continuous variables
- Wilcoxon signed-rank test for non-normally distributed continuous variables
- McNemar test for dichotomous variables
- A secondary completer analysis of HCRU was conducted in the subset of patients who received continuous treatment with OLZ/SAM for the full 12 months of follow-up

Andrew J. Cutler, MD,^{1,2} Hemangi R. Panchmatia, MSc,³ Alejandro G. Hughes, MPH,⁴ Michael J. Doane, PhD,³ Hara E. Oyedeji, CRNP, MS,⁵ Rakesh Jain, MD, MPH⁶ ¹Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY, USA; ³Alkermes, Inc., Eden Prairie, MN, USA; ⁴Optum, In


RESULTS


• After applying the eligibility criteria, the analysis included data from 1287 patients with schizophrenia; of these, 481 (37.4%) were continuously treated with OLZ/SAM for the full 12 months

Table 1. Baseline Patient Demographics

Characteristics	N=1287
Age, years, mean (SD)	38.8 (13.0)
Sex, n (%)	
Female	590 (45.8)
Male	681 (52.9)
Unknown	16 (1.2)
Region, n (%)	
West	431 (33.5)
South	400 (31.1)
Midwest	263 (20.4)
Northeast	193 (15.0)
Insurance type, n (%)	
Medicaid	810 (62.9)
Medicare Advantage	289 (22.5)
Commercial	185 (14.4)
Unknown	3 (0.2)







P*<0.01: *P*<0.001

- disease severity
- (>12-month) OLZ/SAM use

REFERENCES

1. Leucht S, et al. Am J Psychiatry. 2017;174(10):927-42. DOI: 10.1176/appi.ajp.2017.16121358. 2. Firth J, et al. Lancet Psychiatry. 2019;6(8):675-712. DOI: 10.1016/s2215-0366(19)30132-4 3. Doane MJ, et al. Patient Prefer Adherence. 2020;14:2043-54. DOI: 10.2147/ppa.s270020. 4. Doane MJ, et al. BMC Psychiatry. 2023;23(1):245. DOI: 10.1186/s12888-023-04746-4. 5. Martin WF et al. Am J Psychiatry. 2019;176(6):457-67. DOI: 10.1176/appi.ajp.2018.18030280. 6. Correll CU, et al. Am J Psychiatry. 2020;177(12):1168-78. DOI: 10.1176/appi.ajp.2020.19121279. 7. Kahn RS, et al. J Clin Psychiatry. 2023;84(3):22m14674. DOI: 10.4088/JCP.22m14674. 8. Jain R, et al. Presented at: Annual Psych Congress; September 6-10, 2023; Nashville, TN.

Table 2. Baseline Clinical Characteristics

Characteristics	N=1287
Select health characteristics reported by ≥10% of patients during baseline period, n (%)	
Anxiety disorder	707 (54.9)
Obesity	537 (41.7)
Major depressive disorder	534 (41.5)
Any substance use disorder	492 (38.2)
Hypertension	486 (37.8)
Hyperlipidemia	469 (36.4)
Type 2 DM	283 (22.0)
Posttraumatic stress disorder	239 (18.6)
Alcohol use disorder	217 (16.9)
Intentional self-inflicted injury	151 (11.7)
Last antipsychotic use before index date, n (%)	
Any second-generation oral ^a	1083 (84.1)
Any second-generation LAI	102 (7.9)
Any first-generation oral	83 (6.4)
Any first-generation LAI	29 (2.3)
None	32 (2.5)
Other common medications taken during baseline period, n (%)	
Antidepressant	919 (71.4)
Mood stabilizer	735 (57.1)
Antihypertensive	640 (49.7)
Anxiolytic	625 (48.6)
Metformin	264 (20.5)
Patients with type 2 DM	169/264 (64.0)

Olanzapine was used by 52.3% of patients and quetiapine by 10.3% of patients DM, diabetes mellitus; LAI, long-acting injectable

Table 3. Adherence, Persistence, and Discontinuation After OLZ/SAM Initiation

Follow-up ^a treatment patterns	N=1287	
Medication possession ratio, ^b mean (SD)	0.87 (0.19)	
Proportion of days covered, ^c mean (SD)	0.54 (0.37)	
Days persistent, ^d mean (SD)	196.6 (144.6)	
Discontinuation of index therapy, ^e n (%)	806 (62.6)	
^a The follow-up period began on the index date and ended 12 months after the index date. ^b Calculated as sum of days' s divided by number of days in the follow-up period. ^c Calculated as number of days for which medication was available (I number of days in the follow-up period. ^d Measured as the number of days from the index date to the discontinuation of	based on filled prescriptions) divided by the	

index date to the end of the follow-up period (for patients who did not discontinue). ^eDefined as a minimum 45-day gap in therapy. OLZ/SAM, combination olanzapine and samidorphan


• Because of the fixed follow-up time, HCRU and treatment patterns reported herein may not fully capture the effects of longer-term

- Patients continuously treated with OLZ/SAM for the full 12 months had numerically greater reductions in hospital-based HCRU compared with the overall study cohort
- Results indicate that OLZ/SAM initiation may result in clinically meaningful reductions in real-world disease burden (as evidenced by decreases in hospital-based HCRU) and that longer treatment retention (persistence) is associated with improved effectiveness

across all HCRU categories; rates of OP visits were similar

• Average LOS per hospitalization decreased significantly for all-cause, mental health-related, and schizophrenia-related HCRU

Disclosure information, acknowledgments, and copies of this poster can be obtained through this QR (Quick Response) code. These materials are for personal use only and may not be reproduced without permission of Alkermes. For permission contact <u>USMedInfo@Alkermes.com</u>



Healthcare Resource Utilization 12 Months Following Initiation of Olanzapine/Samidorphan: Real-World Assessment of Patients With Schizophrenia

Andrew J. Cutler, MD,^{1,2} Hemangi R. Panchmatia, MSc,³ Alejandro G. Hughes, MPH,⁴ Michael J. Doane, PhD,³ Hara E. Oyedeji, CRNP, MS,⁵ Rakesh Jain, MD, MPH⁶ ¹Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY, USA; ³Alkermes, Inc., Waltham, MA, USA; ⁴Optum, Inc., Eden Prairie, MN, USA; ⁴Optum, Inc., E

AUTHOR DISCLOSURES

AJC has been a consultant to 4M Therapeutics, AbbVie, Acadia, Alfasigma, Alkermes, Anavex Life Sciences, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Intra-Cellular Therapies, Ironshore Pharmaceuticals, Janssen, Karuna, LivaNova, Lundbeck, Luye Pharma, MedAvante-ProPhase, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo, Sunovion, Supernus, Takeda, Teva, Tris Pharma, Vanda, and VistaGen Therapeutics; is on the speakers' bureau and has received honoraria from AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Intra-Cellular Therapies, Ironshore Pharmaceuticals, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Pharma, and Vanda; is on a data safety monitoring board for COMPASS Pathways and Freedom Biosciences; is the chief medical officer of the Neuroscience Education Institute; holds stock options from 4M Therapeutics and Relmada; and receives no royalties.

HRP and MJD are or were employees of Alkermes, Inc., and may own stock/options in the company.

AGH is or was an employee of Optum, Inc., a health services innovation company that received funding from Alkermes, Inc., to conduct this study and analyze the data used for this publication.

HEO has been a consultant to Alkermes, Biogen, Bristol Myers Squibb, Intra-Cellular Therapies, Janssen, Karuna, Neurocrine, Otsuka, Sage Therapeutics, and Sunovion; is on the speakers' bureau and has received honoraria from Alkermes, Bristol Myers Squibb, Intra-Cellular Therapies, Lundbeck, Neurocrine, Otsuka, and Teva; receives no royalties; and holds no stock options.

RJ has acted as consultant for AbbVie, Acadia, Adamas, Alfasigma, Alkermes, Almatica, Axsome, Biogen, Boehringer Ingelheim, Cingulate Therapeutics, Corium, Eisai, Evidera, Impel, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Osmotica, Otsuka, Pamlab, Pfizer, Sage Therapeutics, Shire, Sunovion, Supernus, Takeda, Teva, Transcend Therapeutics, and Viatris; has received speaker/promotional honoraria from AbbVie, Alkermes, Almatica, Axsome, Corium, Eisai, Intra-Cellular Therapies, Ironshore Pharmaceuticals, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Otsuka, Pamlab, Pfizer, Shire, Sunovion, Takeda, Tris Pharmaceuticals, and Viatris; has served on an advisory board for Adamas, Alkermes, Corium, Eisai, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Otsuka, Pamlab, Pfizer, Sage Therapeutics, Shire, Sunovion, Supernus, Takeda, and Teva; and has received research funding from AbbVie, Lilly, Lundbeck, Otsuka, Pfizer, Shire, and Takeda.

ACKNOWLEDGMENTS

This study was sponsored by Alkermes, Inc. Medical writing and editorial support were provided by Peloton Advantage, LLC, an OPEN Health company, and funded by Alkermes, Inc.